Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: SUMOylation inhibition enhances dexamethasone sensitivity in multiple myeloma

Fig. 2

TAK-981 inhibits MM tumor growth and synergizes with Dex effect in vivo. (A) TAK-981 treatment suppresses tumor growth in MM1S-ffGFP xenograft NSG mice. MM1S-ffGFP cells were intravenously (iv) injected to NSG mice via tail vein (1.5 × 106 cells/mouse). After bioluminescence imaging to confirm tumor engraft, mice were randomly assigned to two groups (n = 6) and treated with TAK-981 at 7.5 mg/kg or vehicle twice a week. Tumor growth was monitored by weekly imaging and quantified by Aura software. A Bioluminescence image representative 2 out of 6 mice from each group on Day 10 of treatment. B Tumor growth curve determined by the bioluminescence signal was measured as total photon flux normalized for exposure time and surface area and expressed in units of photons (p) per second per cm2 per steradian (sr). C TAK-981 treatment suppresses tumor growth in MM1R xenograft NSG mice model with synergistic effect in combination with Dex. NSG mice were xenografted by subcutaneously injection of MM1R cells (4 × 106 cells /mouse). Mice were treated with either vehicle, or Dex (3 mg/kg), TAK-981 (10 mg/kg) or combination of both Dex and TAK-981(combo). All agents were treated twice weekly (BIW). Tumor growth was evaluated weekly by caliper measurement and represented as tumor volume (millimeters cubed). Comparison of tumor volume on end point was plotted. D IHC staining of apoptosis marker cleaved PARP and myeloma marker CD138 expression in xenograft tumor tissues. Red bar represents 50 μm. Data were analyzed using unpaired Student t tests: Data presented as mean ± SD. ns, not significant; *, p < 0.05

Back to article page